FTO Regulates Ocular Angiogenesis Via MA-YTHDF2-dependent Mechanism
Overview
Affiliations
Pathological ocular angiogenesis commonly results in visual impairment or even blindness. Unveiling the mechanisms of pathological angiogenesis is critical to identify the regulators and develop effective targeted therapies. Here, we used corneal neovascularization (CNV) model to investigate the mechanism of pathological ocular angiogenesis. We show that N-methyladenosine (mA) mRNA demethylation mediated by fat mass- and obesity-associated protein (FTO) could regulate endothelial cell (EC) function and pathological angiogenesis during CNV. FTO levels are increased in neovascularized corneas and ECs under pathological conditions. In vitro silencing of FTO in ECs results in reduced cellular proliferation, migration, and tube formation under both basal and pathological conditions. Furthermore, FTO silencing attenuates suture-induced CNV in vivo. Mechanically, FTO silencing in ECs could increase mA methylation levels in critical pro-angiogenic genes, such as FAK, leading to decreased RNA stability and increased RNA decay through mA reader YTHDF2. Our study demonstrates that FTO regulates pathological ocular angiogenesis by controlling EC function in an mA-YTHDF2-dependent manner.
Zhou Q, Liu X, Lu H, Li N, Meng J, Huang J J Neuroinflammation. 2024; 21(1):289.
PMID: 39506758 PMC: 11539582. DOI: 10.1186/s12974-024-03279-1.
ALKBH5 Regulates Corneal Neovascularization by Mediating FOXM1 M6A Demethylation.
Wang W, Li H, Qian Y, Li M, Deng M, Bi D Invest Ophthalmol Vis Sci. 2024; 65(12):34.
PMID: 39441582 PMC: 11512564. DOI: 10.1167/iovs.65.12.34.
The role of m6A in angiogenesis and vascular diseases.
Chen K, Li W, Li X iScience. 2024; 27(7):110082.
PMID: 39055919 PMC: 11269316. DOI: 10.1016/j.isci.2024.110082.
Wu Y, Li X, Fu X, Huang X, Zhang S, Zhao N Adv Sci (Weinh). 2024; 11(32):e2403399.
PMID: 39031809 PMC: 11348104. DOI: 10.1002/advs.202403399.
IGF2BP2 Maintains Retinal Pigment Epithelium Homeostasis by Stabilizing PAX6 and OTX2.
Wu S, Li F, Mo K, Huang H, Yu Y, Huang Y Invest Ophthalmol Vis Sci. 2024; 65(6):17.
PMID: 38861275 PMC: 11174093. DOI: 10.1167/iovs.65.6.17.